Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/14/2008

ver

50% of the AIDS virus (HIV-1) protein components in order to stimulate

a broad anti-HIV immune response. The vaccines cannot cause AIDS

because they do not include complete virus. A Phase 1 human trial,

started in April 2006, evaluated the delivery of only 1/10th of the

full dosage and utilized the same vaccine regimen evaluated in the full

dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:
-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate

that they are quite safe and immunogenic following the delivery of

the four full-doses (two of each vaccine) used in the trial's

protocol.

-- The full-dose regimen of GeoVax vaccines continues to be well

tolerated without any type of reaction, mild or systemic, in the

majority of participants.

-- CD4 T-cell responses are high in both the low and full-dose regimens,

84% and 78% of participants.

-- CD8 T-cell responses are present in 42% of the full-dose recipients

and 33% of the 1/10th dose recipients.

-- Antibody responses to the envelope glycoprotein (Env) increased

following the fourth vaccination, and were present in 88% of the

full-dose participants.

-- Delivery of the fourth vaccination increased the frequency and

magnitude of the CD8 T-cell and Antibody responses.

-- During November 2007 through January 2008, GeoVax raised approximately

$3 million in equity capital through a series of privately negotiated

transactions with individual accredited investors and one institutional

investor. These funds, along with the funds received pursuant to the

NIH grant discussed above will be used to offset the Company's ongoing

research and development costs and
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
2. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
6. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
10. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
11. PLC Systems Reports Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... telangiectasia-like disease and Nijmegen breakage syndrome offer ... and cancer vulnerability in people carrying the ... Scientists at St. Jude Children,s Research Hospital ... two related neurological diseases--ataxia telangiectasia-like disease (ATLD) ...
... MannKind Corporation (Nasdaq: MNKD ) ... equivalence of its commercial inhaler to the version of ... deliver AFRESA(TM), MannKind,s ultra rapid acting insulin that recently ... Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:9/1/2015)... ... 01, 2015 , ... USA Medical Card, a leading distributor ... coincide with back-to-school and the start of “sick season” for many households across ... children are sick an average of 8 to 12 times each school year. ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® provides information on defining ... what to look for and expect when searching for resources, as well as ... Canoga Park, CA by CEO, Richard Weatherman and Co-Founder Piroska Zalkadi, AdvantagePlusCaregivers.com® grew ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... communications archiving solution integrated with Alfresco‘s enterprise content management system. PRO Archiver ... save millions of dollars in printing costs by digitizing vast amounts of ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices ... take a look at the topic of arthritis. There are over 100 different types ... interesting arthritis types and statistics in an effort to shed light on this important ...
Breaking Medicine News(10 mins):Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... an issue than youngsters, tastes, studies find, , , MONDAY, April ... issue of supply than demand in the poorest parts of ... children in these rural areas are open to eating more ... not readily available and could become even less so if ...
... published in the April issue of the Journal ... large numbers of physician assistants and nurse practitioners ... hired by general surgery residency programs in the last ... these professionals continue to be in demand. Most have ...
... of Fit by Sara and Susan G. Komen for the Cure, ... DIEGO, April 20 Word is spreading about YOGA 4 THE ... have gathered together to stretch, deep breathe and meditate. Along ... $1,000 in donations for breast cancer. Susan G. Komen for the ...
... 20 The 7th annual FedEx/St. ... 16, 2009 at 7:00 p.m. at the InterContinental Miami Hotel ... premier pediatric cancer research centers. This year,s event will honor ... Thalia , for their generous support of children in need ...
... PAUL, Minn., April 20 More than 2,000 letter carriers ... Out Hunger on May 9, 2009 in an effort ... by the recession. Stamp Out Hunger is the ... locally supports Second Harvest Heartland, the Upper Midwest,s largest hunger-relief ...
... Australia and Israel has identified a genetic variation that ... The finding is published in the latest edition of ... Helen Leonard, who heads the Australian Rett Syndrome Study ... the finding was exciting in that it identifies a ...
Cached Medicine News:Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Surgical education programs have demand for physician assistants and nurse practitioners 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 2Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 4Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 2Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 3Health News:New insight into Rett syndrome severity 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: